Similar articles

• Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.

  Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C, Wallen E. Pruthi RS, et al. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2172-7. doi: 10.1158/1078-0432.CCR-05-2067. Clin Cancer Res. 2006. PMID: 16609031 Clinical Trial.
• Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.

  Narayanan BA, Narayanan NK, Pittman B, Reddy BS. Narayanan BA, et al. Clin Cancer Res. 2004 Nov 15;10(22):7727-37. doi: 10.1158/1078-0432.CCR-04-0732. Clin Cancer Res. 2004. PMID: 15570007
• Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.

  Narayanan BA, Narayanan NK, Pttman B, Reddy BS. Narayanan BA, et al. Prostate. 2006 Feb 15;66(3):257-65. doi: 10.1002/pros.20331. Prostate. 2006. PMID: 16175586
• Prostate cancer chemotherapy in the era of targeted therapy.

  Michael A, Syrigos K, Pandha H. Michael A, et al. Prostate Cancer Prostatic Dis. 2009;12(1):13-6. doi: 10.1038/pcan.2008.32. Epub 2008 Jun 3. Prostate Cancer Prostatic Dis. 2009. PMID: 18521103 Review.
• Immunohistochemical changes in prostate cancer after androgen deprivation therapy.

  Bostwick DG. Bostwick DG. Mol Urol. 2000 Fall;4(3):101-6;discussion 107. Mol Urol. 2000. PMID: 11062363 Review.